title: Noninvasive prenatal screening or advanced diagnostic testing: caveat emptor.
abstract: The past few years have seen extraordinary advances in prenatal genetic practice led by 2 major technological advances; next-generation sequencing of cell-free DNA in the maternal plasma to noninvasively identify fetal chromosome abnormalities, and microarray analysis of chorionic villus sampling and amniotic fluid samples, resulting in increased cytogenetic resolution. Noninvasive prenatal screening of cell-free DNA has demonstrated sensitivity and specificity for trisomy 21 superior to all previous screening approaches with slightly lower performance for other common aneuploidies. These tests have rapidly captured an increasing market share, with substantial reductions in the number of chorionic villus sampling and amniocentesis performed suggesting that physicians and patients regard such screening approaches as an equivalent replacement for diagnostic testing. Simultaneously, many clinical programs have noted significant decreases in patient counseling. In 2012 the Eunice Kennedy Shriver National Institute of Child Health and Human Development funded a blinded comparison of karyotype with the emerging technology of array comparative genomic hybridization showing that in patients with a normal karyotype, 2.5% had a clinically relevant microdeletion or duplication identified. In pregnancies with an ultrasound-detected structural anomaly, 6% had an incremental finding, and of those with a normal scan, 1.6% had a copy number variant. For patients of any age with a normal ultrasound and karyotype, the chance of a pathogenic copy number variant is greater than 1%, similar to the age-related risk of aneuploidy in the fetus of a 38 year old. This risk is 4-fold higher than the risk of trisomy 21 in a woman younger than 30 years and 5- to 10-fold higher than the present accepted risk of a diagnostic procedure. Based on this, we contend that every patient, regardless of her age, be educated about these risks and offered the opportunity to have a diagnostic procedure with array comparative genomic hybridization performed.
authors.affiliation: Comprehensive Genetics PLLC and Department of Obstetrics and Gynecology, New York, NY; Mt Sinai School of Medicine, New York, NY. Electronic address: evans@compregen.com.
authors.forename: Mark I
authors.initials: MI
authors.lastname: Evans
authors.affiliation: Columbia University College of Physicians and Surgeons, New York, NY.
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Wapner
authors.affiliation: Columbia University College of Physicians and Surgeons, New York, NY.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Berkowitz
mesh_terms: D002869:Chromosome Aberrations; D025063:Chromosome Disorders / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000235:genetics; D055028:Comparative Genomic Hybridization; D005260:Female; D005865:Gestational Age; D006801:Humans; D059785:Karyotype; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*; D016216:Ultrasonography, Prenatal
keywords: array comparative genomic hybridization; cell-free fetal DNA; chorionic villus sampling; fetal chromosome abnormalities; maternal serum combined screening; next-generation sequencing